US may not use AstraZeneca vaccine , Dr Anthony Fauci

WHO found that a causal relationship between the vaccines and blood clotting events is considered plausible but is not confirmed

Vaccine advisers to the federal government tell CNN they don't foresee AstraZeneca's Covid-19 vaccine being used in the United States, and even if it were offered, they personally wouldn't take it, given the other available options.

At one point, hopes had been high for AstraZeneca's vaccine, with the US pledging to invest up to $1.2 billion in the vaccine. But questions arose about the accuracy of AstraZeneca's data, and even more significantly, on Wednesday, European drug regulators said there was a possible link between the AstraZeneca vaccine and rare blood clots. Some countries -- more than 70 have authorized the shot -- have now limited its use.

Dr Anthony Fauci told CNN Wednesday that even if the US Food and Drug Administration granted emergency use authorization to AstraZeneca's vaccine, there's no need for it right now in the United States.

"We already have contracted for enough vaccines, from Moderna and from Pfizer and from [Johnson &Johnson]," he said. "There is no plan to immediately start utilizing the AstraZeneca [vaccine] even if it gets approved through the EUA, which it very well might." Fauci said it wasn't because of the AstraZeneca vaccine itself, but rather that it's not necessary in the US right now. "It's not any indictment against the product. We just have a lot of vaccines," he said.

But experts advising the government on vaccine policy say that doesn't paint the whole picture. The three advisers spoke to CNN on the condition of anonymity because of the sensitivities surrounding AstraZeneca's possible application to the FDA.

One adviser told CNN that federal health officials have privately expressed concern that offering AstraZeneca could increase vaccine hesitancy in the US, which is already a problem among some groups.

"I think they're crossing their fingers that AstraZeneca won't apply for emergency use authorization," the adviser said. "This vaccine has a checkered past. There's baggage. Why go down that road if we don't have to?"

Pfizer, Moderna, and Johnson & Johnson's vaccines have excellent safety records, with tens of millions of shots without any reported serious side effects.

"Everyone would raise questions -- 'You're not giving me that new blood clotting vaccine, are you?'" another adviser said, referring to AstraZeneca's vaccine. "Why muddy the waters with a vaccine that comes with a somewhat checkered reputation?"

AstraZeneca's response-

In an email, an AstraZeneca spokesperson declined to respond specifically to Fauci's statements or the advisers' concerns but pointed CNN to AstraZeneca's Phase 3 results in its US trial, which showed that the vaccine was 76% effective at preventing symptomatic Covid-19 and 100% effective at preventing severe or critical disease and hospitalization.
AstraZeneca's vaccine is particularly inexpensive and easier to store and transport than Pfizer and Moderna's vaccines, which makes it especially useful in developing countries.

The spokesperson wrote that the company is committed "to ensuring fair and equitable vaccine access to communities across the world, regardless of geography or income level," and is "very proud of the progress that has been made so far" by the company and its global partners.

Wednesday, AstraZeneca issued a statement responding to findings by the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency.

"Today the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA) completed their assessment of extremely rare blood clotting events with low platelets from over 34 million people vaccinated with AstraZeneca's COVID-19 vaccine in the UK and EU," according to the statement. "[The agencies] came to the view that these events have a possible link to the vaccine and requested they be listed as an extremely rare potential side effect. Overall, both of these reviews reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks."

The statement also said that the World Health Organization found that "a causal relationship between the vaccines and blood clotting events is considered plausible but is not confirmed."

Advisers say they wouldn't take the AstraZeneca vaccine:

CNN spoke with three government vaccine advisers who said they wouldn't take the AstraZeneca shot if they had the option of taking the vaccines made by Pfizer, Moderna or Johnson & Johnson. "All of them keep you out of the hospital and keep you from dying, but those three have a better safety profile," one of the advisers said.
But they also said they would take AstraZeneca's vaccine if it were the only one available to them.

One of the advisers remembered getting an email from an acquaintance in Germany asking if she should get the AstraZeneca vaccine, which was the only one available to her. "I told her yes, absolutely," the adviser said.
The AstraZeneca spokesperson told CNN the company is "currently progressing submission to the FDA for Emergency Use Authorization."

That could put the FDA in a tough spot. A thumbs-down from the FDA -- for whatever reason -- would be problematic for two reasons. First, the FDA is considered the gold standard around the world, and disapproval could cast doubt on a vaccine that is relied upon by dozens of countries and has already been given to nearly 200 million people.

Second, if the FDA doesn't authorize AstraZeneca's vaccine, it could make it awkward for the US to donate its shots -- it has agreements to purchase 300 million doses -- to countries with vaccine shortages. 

"It will look as though we're dumping our second-rate vaccine -- 'We don't want to use it, but they can use it in Mali.' That would look terrible," one of the advisers said. "It's a delicate situation for sure."
An alternative would be to approve the AstraZeneca vaccine, explain that the US doesn't need it, and then donate the US supply to countries with vaccine shortages.

But even so, other countries might still perceive it as dumping an inferior vaccine, the advisers said.
AstraZeneca's spokesperson did not give a timeline for applying to the FDA. On March 22, Ruud Dobber, president of AstraZeneca's biopharmaceuticals business unit, told CNBC that the company planned to apply for a EUA in the first half of April.
Some of the advisers told CNN they hope company executives change their minds.
"If I were AstraZeneca's CEO, I might say, 'what is the purpose of going to the FDA? If we get approved, our vaccine isn't going to be used [in the US], and that will be demonstrated in the press, and our reputation will be besmirched,'" the adviser said.
If they don't apply, the adviser said, the company could "save face and still promote its vaccine around the world."

Story Source: https://edition.cnn.com/2021/04/09/health/vaccine-advisers-astrazeneca-us/index.html 

Tags : #AstraZencaCovidVaccine #VaccineBloodClots #LatestVaccineNews10thApr #Moderna #Pfizer #JohnsonJohnson #WHO #GoldStandardofCOVIDVaccine #VaccinationDriveinUS

About the Author


Team Medicircle

Related Stories

02 Apr

DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?

As the healthcare landscape evolves, initiatives like these will determine the future of medical care in the country.

View
01 Mar

India’s Pharma Revolution: Can New Regulatory Reforms Unleash a $42 Billion Industry?

The potential rewards are enormous a robust, efficient, and competitive pharmaceutical industry that not only fuels domestic growth but also serves as a reliable supplier of essential medicines to the world.

View
27 Feb

India’s Newborns Are Dying from Sepsis And No One Is Talking About It

Newborn sepsis is a complex problem that requires innovative solutions. More funding for research on rapid diagnostic tests, alternative treatments is essential to tackle this growing crisis.

View
26 Feb

The Corporate Invasion of Indian Hospitals: What It Means for You

The question remains: will India’s hospital sector continue on its current trajectory and become a global leader in healthcare, or will the challenges of cost, infrastructure, and regulatory hurdles slow down this remarkable journey.

View
24 Feb

The Great Indian Medical Education Paradox: More Seats, Fewer Students, Collapsing System

The NMC’s strategy to allow non-medical faculty and offer incentives for non-clinical PG courses may help in the short term, but a broader shift in how medical education is structured is necessary.

View
24 Feb

The Dark Side of India’s Pharma Boom: How Banned Drugs Found a New Market in West Africa

Stricter regulations, greater transparency, and proactive enforcement are the only ways to ensure that India’s “pharmacy of the world” reputation is built on trust and safety, not on scandals and cover-ups.

View
21 Feb

India vs. Trump’s Pharma Tariff: The Battle Over Affordable Medicine

Indian pharmaceutical companies may suffer short-term financial setbacks, but they hold the upper hand, because the U.S. needs Indian generics more than India needs the U.S. market.

View
19 Feb

Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery Wave

AIIMS sets a precedent for other hospitals across India to follow. If robotic surgery becomes more widespread, the dream of world-class healthcare for all Indians may not be as distant as it once seemed.

View
19 Feb

Tata’s ₹500-Crore Gamble: Is Healthcare the New Playground for India’s Corporate Giants?

As India’s healthcare sector continues to evolve, corporate giants like Tata are not just participants but key drivers of change.

View
12 Feb

First in India: Dr. Anshumala Shukla-Kulkarni Becomes Asia’s First Certified Endometriosis Specialist

Delayed diagnosis remains one of the biggest challenges. More awareness campaigns, educational programs, and inclusion of endometriosis can help detect the condition early and improve treatment outcomes.

View

-Advertisements-




Trending Now

The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time RestApril 02, 2025
KKR Launches ‘Knight Bite’ – A Digital Series That Serves Up Food, Fun, and Cricket!April 02, 2025
Crompton rolls out its all new range of Aura, Avancer & Jedi Air Coolers for an effortless summer cooling experienceApril 02, 2025
CARE Hospitals, Hi-Tech City Strengthens Orthopaedics Department with Renowned SurgeonsApril 02, 2025
World Autism Awareness Day: Breaking the Chains of Stigma in IndiaApril 02, 2025
From Scroll to Squint: How Reels Are Reshaping Your VisionApril 02, 2025
Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025
CARE Hospitals Launches AI-Powered Non-Invasive Therapy – An innovative modality introduced in Telangana & Andhra PradeshApril 02, 2025
High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?April 02, 2025
DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?April 02, 2025
Medanta Rolls Out ‘Colon Tunnel on Wheels’ to Drive Awareness on Colorectal Cancer Prevention & Early DetectionApril 01, 2025
Zigly launches 2 pet hospitals, opens 4 new stores; expects ARR to more than double in 1-2 yearsApril 01, 2025
University of Leeds Announces International Masters Regional Scholarships for 2025April 01, 2025
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025April 01, 2025
Foundation Stone Laid for Madhav Netralaya Eye Hospital & Research CentreApril 01, 2025
Doomscrolling at Midnight: How Indians Are Sacrificing Sleep for ScreensMarch 31, 2025
Essential Medicines Price Surge: Are Patients Paying the Price?March 31, 2025
Prioritize your health during the holy days of RamzanMarch 31, 2025
Tired of Stomach Cramps? These Simple Foods Can Heal Your GutMarch 31, 2025
Regional growth booming for startups in 2024 - QBO Innovation studyMarch 31, 2025